Comparing Height-Adjusted and Standard Dose Bupivacaine for Spinal Anesthesia in Cesarean Delivery

What this Trial Is About

Researchers are investigating the risks associated with general anesthesia during pregnancy, such as airway difficulties and effects on the newborn, which make intrathecal anesthesia the preferred method for cesarean sections. However, a common side effect of intrathecal anesthesia is arterial hypotension, which depends mainly on the dose of local anesthetic given. There is currently no clear guideline to help anesthetists determine the optimal dose, as a standard dose of 8 to 10 mg of bupivacaine is often used, though lower doses might reduce hypotension risks. This trial compares two doses of intrathecal bupivacaine for cesarean delivery a fixed standard dose of 10 mg combined with morphine and sufentanil, and a height-adjusted dose calculated as 0.05 mg per cm of the patients height, also combined with morphine and sufentanil. The study is randomized and double-blind, evaluating how these dosing strategies affect the rate of arterial hypotension and related anesthesia outcomes. Participants will undergo cesarean section with one of the two dosing regimens, and researchers will monitor blood pressure for 4 hours after administration to measure hypotension rates. Secondary measures include anesthesia efficacy, motor block, need for general anesthesia, vasopressor use, and patient comfort. The study aims to provide clearer guidance on dosing to improve anesthesia safety in pregnant women undergoing cesarean delivery.

Height Adjusted Versus Standardized Dose of Bupivacaine for Spinal Anesthesia